Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open-label study to investigate the safety, tolerability, and exposure of single ascending doses of the antisense oligonucleotide STK-002 in patients with autosomal dominant optic atrophy

Next Previous
Trial Profile

An open-label study to investigate the safety, tolerability, and exposure of single ascending doses of the antisense oligonucleotide STK-002 in patients with autosomal dominant optic atrophy

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STK 002 (Primary)
  • Indications Optic atrophy
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OSPREY
  • Sponsors Stoke Therapeutics

Most Recent Events

  • 04 Nov 2025 According to Stoke Therapeutics media release, the OSPREY study has also been authorized by the European Medicines Authority and European sites are expected to activate in early 2026.
  • 20 Oct 2025 According to Stoke Therapeutics media release, data from the FALCON study (a multicenter, 24-month, prospective natural history non-interventional study) provided important context for the initiation of this study along with future interventional trials.
  • 20 Oct 2025 According to Stoke Therapeutics media release, Dr. Patrick Yu-Wai-Man, M.D., Ph.D., Professor of Ophthalmology and Honorary Consultant Neuro-ophthalmologist at the University of Cambridge, is the the primary investigator on the Phase 1 OSPREY study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top